Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6534
    +0.0011 (+0.17%)
     

  • OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD

    2,349.40
    +6.90 (+0.29%)
     

  • Bitcoin AUD

    97,815.15
    -1,363.76 (-1.38%)
     

  • CMC Crypto 200

    1,331.02
    -65.51 (-4.69%)
     

  • AUD/EUR

    0.6105
    +0.0032 (+0.53%)
     

  • AUD/NZD

    1.0996
    +0.0038 (+0.35%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,718.30
    +287.79 (+1.65%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • Dow Jones

    38,239.66
    +153.86 (+0.40%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021

Novavax, Inc.
·2-min read

GAITHERSBURG, Md., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter 2020 financial results and operational highlights following the close of U.S. financial markets on Monday, March 1, 2021.

Conference call details are as follows:

Date:
Time:
Dial-in number:
Passcode:
Webcast:

March 1, 2021
4:30 p.m. U.S. Eastern Time (ET)
(877) 212-6076 (Domestic) or (707) 287-9331 (International)
3797013
www.novavax.com/events


Conference call and webcast replay:

Date:
Dial-in number:
Passcode:
Webcast:

Starting at 7:30 p.m. ET, March 1, 2021
(855) 859-2056 (Domestic) or (404) 537-3406 (International)
3797013
www.novavax.com/events, until June 1, 2021

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

ADVERTISEMENT

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Jennifer Porcelli | 617-974-8659
jporcelli@soleburytrout.com

Media
Amy Speak | 617-420-2461
Laura Keenan | 410-419-5755
media@novavax.com